The panel largely responsible for recommending which drugs the UK’s National Health Service (NHS) should provide may discourage use of the CBD-based drug Epidyolex
Written by CannIntelligence || 29th August 2019 || News analysis | Health and science | Regulation and legislation | Europe United Kingdom